



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

Addiction Psychiatry

Article-Assessment Program Article List

Updated: January 2026

The following articles are being used in the American Board of Psychiatry and Neurology's Article Assessment program for the current year. Please note that these articles are subject to change without notice. Please consult the ABPN Continuing Certification testing site for the most up-to-date information about articles that are currently active.

The articles listed are subject to change. Please note that pay status is also subject to change and is set by the publisher of the journal. ABPN has no control over the cost of journal articles.

If you are having trouble accessing articles listed free to professional society members, please contact the professional society directly for assistance.

When accessing articles from publisher websites, we recommend that you download a copy of a file once and consult that copy when taking exams. Some sites may limit the number of articles that you can access per month without a subscription; in those cases, downloading or viewing an article repeatedly may cause you to be blocked from accessing any articles until the next month begins.

These articles may be protected by copyright. Please refer to the publisher's copyright notice and policies.

© 2026, American Board of Psychiatry and Neurology, Inc. All rights reserved.

Topic 1 - Screening and Evaluation for Addictive Disorders, Epidemiology, Prevention

	Author	Title	Journal	Edition	Cost	Professionalism?
1	Jones G, Herrmann F, Wang E	<u>Associations between individual hallucinogens and hallucinogen misuse among U.S. Adults who recently initiated hallucinogen use</u>	Addict Behav Rep	2023 Aug 12;18:100513	No cost	
2	Nelson LF, Weitzman ER, Levy S	<u>Prevention of Substance Use Disorders</u>	Medical Clinics of North America	2022 Jan;106(1):153-168	Purchase May Be Required	
3	Levy S, Brogna M, Minegishi M, et al	<u>Assessment of Screening Tools to Identify Substance Use Disorders Among Adolescents</u>	JAMA	2023 May 1;6(5):e2314422	No cost	
4	White AM	<u>Gender Differences in the Epidemiology of Alcohol Use and Related Harms in the United States</u>	Alcohol Research Current Reviews	2020 Oct 29;40(2):01	No cost	
5	Myran DT, Pugliese M, Xiao J, et al	<u>Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder</u>	JAMA Psychiatry	2025 Feb 1;82(2):142-150	No cost	
6	Donaldson T, Dang EP, Pierce-Bulger M, et al	<u>Importance of Fetal Alcohol Spectrum Disorders Prevention and Intervention</u>	Subst Use Addctn J	2024 Nov 28:29767342241300797	Purchase May Be Required	

Topic 2 - Alcohol and Related Disorders

	Author	Title	Journal	Edition	Cost	Professionalism?
1	Kranzler HR	<u>Overview of Alcohol Use Disorder</u>	Am J Psychiatry	2023 Aug 1;180(8):565-572	No cost	
2	Pourmand A, AlRemeithi R, Kartiko S, et al	<u>Evaluation of phenobarbital based approach in treating patient with alcohol withdrawal syndrome: A systematic review and meta-analysis</u>	Am J Em Med	2023 Jul;69:65-75	Purchase May Be Required	
3	Kelly JF, Abry A, Ferri M, et al	<u>Alcoholics Anonymous and 12-Step Facilitation Treatments for Alcohol Use Disorder: A Distillation of a 2020 Cochrane Review for Clinicians and Policy Makers</u>	Alcohol and Alcoholism	2020 Oct 20;55(6):641-651	No cost	
4	Anton RF, Latham P, Voronin K, et al	<u>Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial</u>	JAMA Internal Medicine	2020 May 1;180(5):728-736	No cost	
5	Murthy V	<u>Alcohol and Cancer Risk 2025 The Surgeon General's Advisory</u>	US DHHS	2025	No cost	
6	Hahn JA, Fatch R, Barnett NP, et al	<u>Phosphatidylethanol vs Transdermal Alcohol Monitoring for Detecting Alcohol Consumption Among Adults</u>	JAMA Netw Open	2023 Sep 5;6(9):e2333182	No cost	

Topic 3 - Cannabis and Related Disorders

	Author	Title	Journal	Edition	Cost	Professionalism?
1	Gilman JM, Schuster RM, Potter KW, et al	<u>Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults: A Randomized Clinical Trial</u>	JAMA Network Open	2022 Mar 1;5(3):e22210 6	No cost	
2	Gorelick, D	<u>Cannabis-Related Disorders and Toxic Effects</u>	N Engl J Med	Dec 14;389(24)	Purchase May Be Required	
3	Myran DT, Harrison LD, Pugliese M, et al	<u>Transition to Schizophrenia Spectrum Disorder Following Emergency Department Visits Due to Substance Use With and Without Psychosis</u>	JAMA Psychiatry	2023 Nov 1;80(11):1169- 1174.	Free to Professional Society Members	
4	Meier MH, Caspi A, R Knodt A, et al	<u>Long-Term Cannabis Use and Cognitive Reserves and Hippocampal Volume in Midlife</u>	American Journal of Psychiatry	2022 May;179(5):36 2-374	No cost	
5	Le Foll B, Tang VM, Rueda S, et al	<u>Cannabis use disorder: from neurobiology to treatment</u>	J Clin Invest	2024 Oct 15;134(20):e1 72887	No cost	
6	Rodas JD, Sorkhou M, George TP	<u>Contingency Management for Treatment of Cannabis Use Disorder in Co-Occurring Mental Health Disorders: A Systematic Review</u>	Brain Sci	2022 Dec 23;13(1):36	No cost	

Topic 4 - Opioids and Related Disorders

	Author	Title	Journal	Edition	Cost	Professionalism?
1	Ahmed S, Bhivandkar S, Lonergan BB, et al	<u>Microinduction of Buprenorphine/Naloxone: A Review of the Literature</u>	The American Journal on Addictions	2021 Jul;30(4):305-315	Purchase May Be Required	
2	Connery HS, Taghian N, Kim J, et al	<u>Suicidal motivations reported by opioid overdose survivors: A cross-sectional study of adults with opioid use disorder</u>	Drug and Alcohol Dependence	2019 Dec 1;205:107612	Purchase May Be Required	
3	Frankeberger J, Jarlenski M, Krans EE, et al	<u>Opioid Use Disorder and Overdose in the First Year Postpartum: A Rapid Scoping Review and Implications for Future Research</u>	Matern Child Health J	2023 Jul;27(7):1140-1155	Purchase May Be Required	
4	Marsden J, Kelleher M, Gilvarry E, et al	<u>Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial</u>	E Clinical Medicine	2023 Nov 17;66:102311	No cost	
5	Shulman M, Greiner MG, Tafessu HM, et al	<u>Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial</u>	JAMA Netw Open	2024 May 1;7(5):e249744	No cost	
6	D'Onofrio G, Herring AA, Perrone J, et al	<u>Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal</u>	JAMA Netw Open	2024 Jul 1;7(7):e2420702	No cost	

Topic 5 - Stimulants and Related Disorders

	Author	Title	Journal	Edition	Cost	Professionalism?
1	Moszczyńska A	<u>Current and Emerging Treatments for Methamphetamine Use Disorder</u>	Curr Neuropharmacol	2021;19(12):2077-2091	Purchase May Be Required	
2	McCabe SE, Schulenberg JE, Wilens TE, et al	<u>Cocaine or Methamphetamine Use During Young Adulthood Following Stimulant Use for Attention-Deficit/Hyperactivity Disorder During Adolescence</u>	JAMA Network Open	2023 Jul 3;6(7):e23222650	No cost	
3	Palis H, Xavier C, Dobrer S, et al	<u>Concurrent use of opioids and stimulants and risk of fatal overdose: A cohort study</u>	BMC Public Health	2022 Nov 15;22(1):2084	No cost	
4	Ciccarone D, Shoptaw S	<u>Understanding Stimulant Use and Use Disorders in a New Era</u>	Med Clin North America	2022 Jan;106(1)	Purchase May Be Required	
5	Sharafi H, Bakouni H, McAnulty C, et al	<u>Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials</u>	Society for the Study of Addiction	2024 Feb;119(2):211-224	No cost	
6	Li MJ, Shoptaw SJ	<u>Clinical management of psychostimulant withdrawal: review of the evidence</u>	Addiction	2023 Apr;118(4):750-762	Purchase May Be Required	

Topic 6 - Tobacco and Related Disorders (Vaping, Nicotine products)

	Author	Title	Journal	Edition	Cost	Professionalism?
1	Vlad C, Arnsten JH, Nahvi S	<u>Achieving Smoking Cessation Among Persons with Opioid Use Disorder</u>	CNS Drugs	2020 Apr;34(4):367-387	Purchase May Be Required	
2	Nollen NL, Ahluwalia JS, Sanderson Cox L, et al	<u>Assessment of Racial Differences in Pharmacotherapy Efficacy for Smoking Cessation: Secondary Analysis of the EAGLES Randomized Clinical Trial</u>	JAMA	2021 Jan 4;4(1):e2032053	No cost	
3	Kaplan B, Galiatsatos P, Breland A, et al	<u>Effectiveness of ENDS, NRT and medication for smoking cessation among cigarette-only users: a longitudinal analysis of PATH Study wave 3</u>	Tobacco Control	2023 May;32(3):302-307	No cost	
4	Caponnetto P, Spicuzza L, Campagna D, et al	<u>Varenicline for smoking cessation in individuals who smoke cigarettes and use electronic cigarettes: a double-blind, randomised, placebo-controlled phase 3 trial</u>	E Clinical Medicine	2023 Nov 21;66:102316	No cost	
5	Cinciripini PM, Green CE, Shete S, et al	<u>Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial</u>	JAMA	2024 May 28;331(20):1722-1731	No cost	
6	Kypriotakis G, Cinciripini PM, Green CE, et al	<u>Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial</u>	Am J Psychiatry	2025 Feb 1;182(2):174-186	Free to Professional Society Members	

Topic 7 - Other Substance Use Disorders (Sedatives, Hypnotics, Anxiolytics, Club Drugs, Inhalants, Hallucinogens), Behavioral Addictions

	Author	Title	Journal	Edition	Cost	Professionalism?
1	Bonnecaze AK, O'Connor T, Burns CA	<u>Harm Reduction in Male Patients Actively Using Anabolic Androgenic Steroids (AAS) and Performance-Enhancing Drugs (PEDs): a Review</u>	Journal of General Internal Medicine	2021 Jul;36(7):2055-2064	No cost	
2	D'Orazio J, Nelson L, Perrone J, et al	<u>Xylazine Adulteration of the Heroin-Fentanyl Drug Supply: A Narrative Review</u>	Annals of Internal Medicine	2023 Oct;176(10):1370-1376	Purchase May Be Required	
3	Kleinman RA, Weiss RD	<u>Benzodiazepine-Involved Overdose Deaths in the USA: 2000-2019</u>	Journal of General Internal Medicine	2022 Jun;37(8):2103-2109	No cost	
4	Palamar JJ, Fitzgerald ND, Grundy DJ, et al	<u>Characteristics of poisonings involving ketamine in the United States, 2019-2021</u>	J Psychopharmacol	2023 Aug;37(8):802-808	Purchase May Be Required	
5	Smith KE, Epstein DH, Weiss ST	<u>Controversies in Assessment, Diagnosis, and Treatment of Kratom Use Disorder</u>	Curr Psychiatry Rep	2024 Sep;26(9):487-496	No cost	
6	Brand M, Antons S, Bóthe B, et al	<u>Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice</u>	Am J Psychiatry	2025 Feb 1;182(2):155-163	Purchase May Be Required	

Topic 8 - Dual Diagnoses and Substance-induced Disorders

	Author	Title	Journal	Edition	Cost	Professionalism?
1	Martin EL, Neelon B, Brady KT, et al	<u>Differential prevalence of Adverse Childhood Experiences (ACEs) by gender and substance used in individuals with cannabis, cocaine, opioid, and tobacco use disorders</u>	The American Journal of Drug and Alcohol Abuse	2023 Mar 4;49(2):190-198	No cost	
2	Hien DA, Morgan-López AA, Saavedra LM, et al	<u>Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders</u>	The American Journal of Psychiatry	2023 Feb 1;180(2):155-166	No cost	
3	Clark AE, Goodwin SR, Marks RM, et al.	<u>A Narrative Literature Review of the Epidemiology, Etiology, and Treatment of Co-Occurring Panic Disorder and Opioid Use Disorder</u>	J Dual Diagnosis	2021 Oct-Dec;17(4)	No cost	
4	Kast KA, Rao V, Wilens TE	<u>Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder and Retention in Outpatient Substance Use Disorder Treatment: A Retrospective Cohort Study</u>	J Clin Psychiatry	2021 Feb 23;82(2)	No cost	
5	McCarthy SDS, Xiao J, Pugliese M, et al	<u>Changes in cannabis involvement in emergency department visits for anxiety disorders after cannabis legalization: a repeated cross-sectional study</u>	Lancet Reg Health Am	2024 Jun 13;36:100815	No cost	
6	Neyra A, Parro-Torres C, Ros-Cucurull E, et al	<u>Management of schizophrenia and comorbid substance use disorders: expert review and guidance</u>	Annals of General Psychiatry	2024 Oct 30;23(1):40	No cost	

Topic 9 - Psychosocial Therapy and Psychotherapeutic Approaches and Principles in Treatment

	Author	Title	Journal	Edition	Cost	Professionalism?
1	Sherman ADF, Balthazar M, Zhang W, et al	<u>Seeking safety intervention for comorbid post-traumatic stress and substance use disorder: A meta-analysis</u>	Brain and Behavior	2023 May;13(5)	No cost	
2	Stack E, Hildebran C, Leichtling G, et al	<u>Peer Recovery Support Services Across the Continuum: In Community, Hospital, Corrections, and Treatment and Recovery Agency Settings - A Narrative Review</u>	J Addict Med	2022 Jan-Feb 01;16(1):93-100	Purchase May Be Required	
3	Cooperman NA, Lu SE, Hanley AW, et al	<u>Telehealth Mindfulness-Oriented Recovery Enhancement vs Usual Care in Individuals With Opioid Use Disorder and Pain: A Randomized Clinical Trial</u>	JAMA Psychiatry	2023 Dec 7:e235138	No cost	
4	Sugarman DE, Meyer LE, Reilly ME, et al	<u>Women's and men's experiences in group therapy for substance use disorders: A qualitative analysis</u>	American Journal On Addictions	2022 Jan;31(1):9-21	Purchase May Be Required	
5	Amin-Esmaeili M, Farokhnia M, et al	<u>Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials</u>	Addiction	2024 May;119(5):833-843	Purchase May Be Required	
6	Cazalis A, Lambert L, Auriacombe M	<u>Stigmatization of people with addiction by health professionals: Current knowledge. A scoping review</u>	Drug Alcohol Depend Rep	2023 Oct 24;9:100196	No cost	Yes

Topic 10 - Special Populations (Children, Geriatric, LGBT, Pregnancy, Prisons, Homeless, etc); Other topics (Emerging issues, healthcare delivery, special settings)

	Author	Title	Journal	Edition	Cost	Professionalism?
1	Oladunjoye AF, Li E, Aneni K, et al	Cannabis use disorder, suicide attempts, and self-harm among adolescents: A national inpatient study across the United States	PLoS One	2023 Nov 30;18(11):e0294303	No cost	
2	Lo JO, Hedges JC, Girardi G	Impact of cannabinoids on pregnancy, reproductive health, and offspring outcomes	Am J Obstet Gynecol.	2022;227(4):571-581	Purchase May Be Required	
3	Randall-Kosich O, Whitaker DJ, Guastaferrero WP, et al	Predicting drug court graduation: Examining the role of individual and programmatic characteristics	Journal of Substance Abuse Treatment	2022 Apr;135:108654	Purchase May Be Required	
4	Baranyi G, Fazel S, Langerfeldt SD	The prevalence of comorbid serious mental illnesses and substance use disorders in prison populations: a systematic review and meta-analysis	Lancet Public Health	2022 Jun;7(6):e557-e568	No cost	
5	Straub L, Bateman BT, Hernández-Díaz S, et al	Comparative Safety of In Utero Exposure to Buprenorphine Combined With Naloxone vs Buprenorphine Alone	JAMA	2024 Sep 10;332(10):805-816	No cost	
6	Fountoulakis KN, Saitis A, Schatzberg AF	Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis	Am J Psychiatry	2025 Jan 29:appiajp20240515	Free to Professional Society Members	

The articles listed are subject to change. Please note that pay status is also subject to change and is set by the publisher of the journal. ABPN has no control over the cost of journal articles.

If you are having trouble accessing articles listed free to professional society members, please contact the professional society directly for assistance.

When accessing articles from publisher websites, we recommend that you download a copy of a file once and consult that copy when taking exams. Some sites may limit the number of articles that you can access per month without a subscription; in those cases, downloading or viewing an article repeatedly may cause you to be blocked from accessing any articles until the next month begins.

Some or all of these articles may be protected by copyright. Please refer to the publisher's copyright notice and policies.